APA (7th ed.) Citation

Curtis, J. R., Yamaoka, K., Chen, Y., Bhatt, D. L., Gunay, L. M., Sugiyama, N., . . . Gómez-Reino, J. J. (2023). Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial. Annals of the rheumatic diseases, 82(3), 331-343. https://doi.org/10.1136/ard-2022-222543

Chicago Style (17th ed.) Citation

Curtis, Jeffrey R., et al. "Malignancy Risk with Tofacitinib Versus TNF Inhibitors in Rheumatoid Arthritis: Results from the Open-label, Randomised Controlled ORAL Surveillance Trial." Annals of the Rheumatic Diseases 82, no. 3 (2023): 331-343. https://doi.org/10.1136/ard-2022-222543.

MLA (9th ed.) Citation

Curtis, Jeffrey R., et al. "Malignancy Risk with Tofacitinib Versus TNF Inhibitors in Rheumatoid Arthritis: Results from the Open-label, Randomised Controlled ORAL Surveillance Trial." Annals of the Rheumatic Diseases, vol. 82, no. 3, 2023, pp. 331-343, https://doi.org/10.1136/ard-2022-222543.